Published in Infect Immun on October 29, 2007
Regulation of neurotoxin production and sporulation by a Putative agrBD signaling system in proteolytic Clostridium botulinum. Appl Environ Microbiol (2010) 1.30
Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl Environ Microbiol (2009) 1.09
Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr Purif (2010) 1.05
Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS One (2010) 1.01
Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype. PLoS One (2015) 0.91
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents. Br J Pharmacol (2010) 0.89
Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun (2009) 0.89
Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A. Biochem Biophys Res Commun (2011) 0.87
Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine (2011) 0.81
DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge. Hum Vaccin Immunother (2015) 0.81
Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B. Clin Vaccine Immunol (2010) 0.81
Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clin Vaccine Immunol (2008) 0.80
Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain. mSphere (2016) 0.79
Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein. PLoS One (2011) 0.78
Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing. Toxins (Basel) (2015) 0.77
Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr Top Med Chem (2014) 0.77
Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor. Mol Immunol (2013) 0.77
Identification and characterization of a novel botulinum neurotoxin. Nat Commun (2017) 0.77
Adenovirus F protein as a delivery vehicle for botulinum B. BMC Immunol (2010) 0.76
DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E. Hum Vaccin Immunother (2013) 0.75
Vaccines against Botulism. Toxins (Basel) (2017) 0.75
Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins (Basel) (2017) 0.75
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol (1998) 4.21
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun (2005) 3.06
Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes. Genome Res (2007) 2.67
Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature (2006) 2.20
Conjugative transfer of clostridial shuttle vectors from Escherichia coli to Clostridium difficile through circumvention of the restriction barrier. Mol Microbiol (2002) 2.19
Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon (2001) 2.05
Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature (2006) 1.97
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol (2003) 1.81
Development of vaccines for prevention of botulism. Biochimie (2000) 1.73
The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol (2004) 1.73
Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem (2004) 1.67
Basic immunological aspects of botulinum toxin therapy. Mov Disord (2004) 1.62
Purification of Clostridium botulinum type A neurotoxin. Methods Mol Biol (2000) 1.47
Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol (2004) 1.42
Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment C of botulinum neurotoxin, serotype A. Biotechnol Bioeng (2000) 1.31
Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol (1999) 1.26
Induction of an immune response by oral administration of recombinant botulinum toxin. Infect Immun (1997) 1.21
Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun (2001) 1.20
Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry (2002) 1.16
Development of recombinant vaccines for botulinum neurotoxin. Toxicon (1998) 1.15
Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes. Biochemistry (2007) 1.14
Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun (2005) 1.10
Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry (2006) 1.04
Botulinum neurotoxin B-host receptor recognition: it takes two receptors to tango. Nat Struct Mol Biol (2007) 0.93
Infant botulism and treatment with BIG-IV (BabyBIG). Pediatr Infect Dis J (2007) 0.92
Conjugative transfer of the Escherichia coli-Clostridium perfringens shuttle vector pJIR1457 to Clostridium botulinum type A strains. Plasmid (1998) 0.92
Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif (2000) 0.89
Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115. Protein Expr Purif (2005) 0.88
Characterization of neurotoxin mutants in Clostridium botulinum type A. Clin Infect Dis (1997) 0.80
Rapid SNP discovery and genetic mapping using sequenced RAD markers. PLoS One (2008) 13.64
Population genomics of parallel adaptation in threespine stickleback using sequenced RAD tags. PLoS Genet (2010) 7.05
The Group Health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff (Millwood) (2010) 6.60
Rapid and cost-effective polymorphism identification and genotyping using restriction site associated DNA (RAD) markers. Genome Res (2006) 5.80
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
Construction and application for QTL analysis of a Restriction Site Associated DNA (RAD) linkage map in barley. BMC Genomics (2011) 3.42
Single-cell microbiology: tools, technologies, and applications. Microbiol Mol Biol Rev (2004) 2.53
RAD marker microarrays enable rapid mapping of zebrafish mutations. Genome Biol (2007) 2.07
Bacterial cytotoxins: targeting eukaryotic switches. Nat Rev Microbiol (2005) 1.98
Local de novo assembly of RAD paired-end contigs using short sequencing reads. PLoS One (2011) 1.98
Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature (2006) 1.97
SNP discovery and genotyping for evolutionary genetics using RAD sequencing. Methods Mol Biol (2011) 1.96
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Curr Microbiol (2003) 1.83
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol (2003) 1.81
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
High-density detection of restriction-site-associated DNA markers for rapid mapping of mutated loci in Neurospora. Genetics (2007) 1.78
Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell (2008) 1.66
Analysis of neurotoxin cluster genes in Clostridium botulinum strains producing botulinum neurotoxin serotype A subtypes. Appl Environ Microbiol (2008) 1.62
Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins. J Biol Chem (2003) 1.60
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem (2006) 1.54
Phylogenetic analysis of Clostridium botulinum type A by multi-locus sequence typing. Microbiology (2008) 1.52
Plasmid encoded neurotoxin genes in Clostridium botulinum serotype A subtypes. Biochem Biophys Res Commun (2007) 1.52
Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob Agents Chemother (2003) 1.47
The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr Purif (2004) 1.45
Genetic homogeneity of Clostridium botulinum type A1 strains with unique toxin gene clusters. Appl Environ Microbiol (2008) 1.44
Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry (2009) 1.41
A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett (2007) 1.40
Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci U S A (2004) 1.40
Subunit vaccine against the seven serotypes of botulism. Infect Immun (2007) 1.39
Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol (2008) 1.35
In vivo rho GTPase-activating protein activity of Pseudomonas aeruginosa cytotoxin ExoS. Infect Immun (2002) 1.35
Regulation of neurotoxin complex expression in Clostridium botulinum strains 62A, Hall A-hyper, and NCTC 2916. Anaerobe (2004) 1.30
Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem (2007) 1.30
Bleeding stomal varices: case series and systematic review of the literature. Clin Gastroenterol Hepatol (2008) 1.29
Safety of using a computerized rounding and sign-out system to reduce resident duty hours. Acad Med (2010) 1.29
Identification of a lycopene beta-cyclase required for bacteriorhodopsin biogenesis in the archaeon Halobacterium salinarum. J Bacteriol (2002) 1.28
Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A (2009) 1.26
Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum. FEMS Microbiol Lett (2004) 1.25
Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog (2011) 1.24
Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods (2010) 1.21
Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci (2012) 1.21
Characterization of Clostridium botulinum strains associated with an infant botulism case in the United Kingdom. J Clin Microbiol (2005) 1.18
Intracellular localization modulates targeting of ExoS, a type III cytotoxin, to eukaryotic signalling proteins. Mol Microbiol (2002) 1.17
Effects of purification on the bioavailability of botulinum neurotoxin type A. Toxicology (2008) 1.16
Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS. J Biol Chem (2002) 1.16
Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst (2013) 1.16
SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog (2010) 1.15
Spreading a medical home redesign: effects on emergency department use and hospital admissions. Ann Fam Med (2013) 1.15
Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol (2007) 1.15
A survey of new temperature-sensitive, embryonic-lethal mutations in C. elegans: 24 alleles of thirteen genes. PLoS One (2011) 1.15
Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc (2010) 1.14
Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes. Biochemistry (2007) 1.14
Intracellular membrane localization of pseudomonas ExoS and Yersinia YopE in mammalian cells. J Biol Chem (2003) 1.14
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci U S A (2011) 1.12
Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem (2009) 1.12
Amyloidosis presenting as lower gastrointestinal hemorrhage. WMJ (2008) 1.11
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J Biol Chem (2008) 1.11
Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E. J Biol Chem (2007) 1.10
Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun (2013) 1.10
Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun (2005) 1.10
Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl Environ Microbiol (2009) 1.09
Elevated CO2 suppresses specific Drosophila innate immune responses and resistance to bacterial infection. Proc Natl Acad Sci U S A (2009) 1.09
Genomic patterns of introgression in rainbow and westslope cutthroat trout illuminated by overlapping paired-end RAD sequencing. Mol Ecol (2013) 1.09
Conjugative botulinum neurotoxin-encoding plasmids in Clostridium botulinum. PLoS One (2010) 1.08